JPMorgan analyst Brian Cheng downgraded Pliant Therapeutics (NASDAQ: PLRX) from Neutral to Underweight.The analyst comments: "The story for PLRX has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE